NEW YORK (GenomeWeb News) – Becton Dickinson today said that its BD Diagnostics unit will collaborate with Lab21 on the development of oncology assays to run on the BD Max molecular diagnostic system.

Cambridge, UK-based Lab21 will develop PCR-based tests for a series of oncology markers, while BD will be responsible for manufacturing and commercializing the tests worldwide. The Franklin Lakes, NJ-based medical products and research tools firm said that the first two assays developed under the collaboration will target KRAS and BRAF mutations.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.